Work Here?
About Bodyport
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$15.4M
Headquarters
San Francisco, California
Founded
2015
Overview
Bodyport focuses on helping individuals manage chronic conditions, especially heart failure. The company offers at-home devices that use a biomarker platform to noninvasively measure various hemodynamic biomarkers related to heart health. This technology enables patients and their healthcare teams to monitor changes in heart health more effectively, which can lead to fewer hospital visits and better health outcomes. Bodyport distinguishes itself from competitors by providing actionable health insights through its proprietary platform, which not only sells devices but may also offer subscription services for continuous health monitoring. The main goal of Bodyport is to empower patients to take control of their health and improve their quality of life.
Simplify's Take
What believers are saying
- The rise of remote patient monitoring technologies presents a significant market opportunity.
- FDA guidance encourages innovation in noninvasive monitoring, aligning with Bodyport's offerings.
- Demand for subscription-based health monitoring services is increasing, boosting potential revenue.
What critics are saying
- Increased competition from companies like Eko Devices with similar cardiac monitoring solutions.
- Potential regulatory challenges as FDA tightens guidelines on digital health devices.
- Data privacy concerns due to stricter legislation like the California Privacy Rights Act.
What makes Bodyport unique
- Bodyport offers noninvasive hemodynamic biomarker measurement for heart failure management.
- The company integrates a sophisticated biomarker platform into user-friendly, at-home devices.
- Bodyport's partnership with Geisinger enhances its credibility and market reach.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$15.4M
Below
Industry Average
Funded Over
2 Rounds
Y CombinatorIndustry standards
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 4%Bodyport and Geisinger to launch innovative Heart failure monitoring program.
Bodyport Inc. today introduced SCALE-HF, a multi-phase study to develop and validate a composite index to predict heart failure events using multiple noninvasive hemodynamic biomarkers gathered when a patient stands on the Bodyport Cardiac Scale.
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, announced today the appointment of Jim Pursley to the company’s board of directors.
Biomarker-guided digital therapeutics company Bodyport has appointed medtech industry veteran John Lipman as its new CEO.
Jess asks me about Lumeon raising a $30M Series D for their care orchestration centers, Nurx raising a $22M Series C to develop out its online pharmacy presence, Thirty Madison getting $47M and Johnson & Johnson is an investor this round, Bodyport closing an $11.2 M Series A for their weighing scale platform that can detect early cardiovascular disease, and Kumanu raising a $3M Series A to grow out its platform that helps people figure out their lives’ purpose.
There are no jobs for Bodyport right now.
Find jobs on Simplify and start your career today
About Bodyport
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$15.4M
Headquarters
San Francisco, California
Founded
2015
There are no jobs for Bodyport right now.
Find jobs on Simplify and start your career today